10:10:12 EDT Sun 23 Jun 2024
Enter Symbol
or Name

Cybin Inc
Symbol CYBN
Shares Issued 743,885,052
Close 2024-04-17 C$ 0.51
Market Cap C$ 379,381,377
Recent Sedar Documents

Cybin publishes CYB210010 research manuscript

2024-04-18 13:00 ET - News Release

Mr. Doug Drysdale reports


Cybin Inc.'s research manuscript, entitled "Synthesis and Structure-Activity Relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of CYB210010: A potent, orally bioavailable and long-acting serotonin 5-HT2 receptor agonist," has been published in the Journal of Medicinal Chemistry, a prestigious biweekly peer-reviewed publication.

"We are delighted that our research on phenethylamine serotonin 5-HT2 receptor agonists was published in this important journal," said Doug Drysdale, chief executive officer of Cybin. "This study is an example of our expanding scope of innovative development work beyond our clinical tryptamine programs. This publication is a testament not only to our scientific leadership in the field of 5-HT2 receptor agonists, the receptor family believed to mediate the therapeutic effects of classic psychedelics, but also to the depth and breadth of our expertise as we continue to advance the study of the role of next-generation psychedelic-based treatment options for mental health and neurological disorders."

"In the past decade, there has been a revival of interest in serotonin (5-HT)-based psychedelics as pharmacotherapeutics for neuropsychiatric disorders," said Geoff Varty, PhD, head of R&D (research and development) of Cybin. "Given the clinical potential of 2C-X phenethylamines, our studies explored the SARs of a broad range of 2C-X analogs, focusing on 4-thio derivatives, to identify novel 5-HT2 receptor ligands with unique pharmacodynamic (PD) and pharmacokinetic (PK) properties. We synthesized 39 proprietary 4-substituted-2,5-dimethoxyphenethylamines, and these phenethylamines were profiled for their ability to interact with the serotonin system and to induce psychedelic-like effects in preclinical models. This research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2 receptor agonist with favourable PK and PD properties," concluded Dr. Varty.

Future investigations will focus on the development of CYB210010 and related molecules as novel therapeutics for psychiatric and neurological disorders with unmet needs.

Title:  Synthesis and structure-activity relationships of 2,5-dimethoxy-4-substituted phenethylamines and the discovery of CYB210010: A potent, orally bioavailable and long-acting serotonin 5-HT2 receptor agonist

Authors:  Dr. Varty, Clint Canal, Tina Mueller, Josh Hartsel, Richa Tyagi, Ken Avery, Mike Morgan, Amy Reichelt, Pradip Pathare, Erik Stang, Mike Palfreyman and Alex Nivorozhkin

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin's goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analogue for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT (N,N-dimethyltryptamine) molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.

Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.